February 14, 2025

Study: Patients Trust Female Docs Less

Study findings and an interview with the lead investigator.

Conexiant

February 12, 2025

Immunosuppressive Therapy Withdrawal and Renal Relapse Risks

Study finds prolonged immunosuppressive therapy duration and gradual tapering reduce renal relapse risk in proliferative lupus nephritis.

Conexiant

February 11, 2025

Flares Increase Damage Risk in Patients With SLE

Flares in SLE patients increase risk of damage accrual by 7% with each additional flare, highlighting the importance of flare prevention in disease management.

Conexiant

February 07, 2025

Hematologic Indicators Linked to Alopecia Areata Severity

Researchers analyze hematological ratios in alopecia areata severity assessment.

Conexiant

February 05, 2025

FDA Approves Tocilizumab Biosimilar

FDA approves AVTOZMA after phase III trial confirms equivalence in efficacy, safety, and pharmacokinetics for RA and other inflammatory conditions.

Conexiant

February 03, 2025

Key Comorbidities Elevate Risk of Severe Alopecia Areata

Study finds bronchial asthma, dermatitis, and thyroiditis significantly increase risk for early-onset, severe, and prolonged alopecia areata.

Conexiant

January 29, 2025

Fracture Infection Treatment: Oral vs Intravenous Data

A trial compared oral versus intravenous antibiotics for fracture-related infections.

Conexiant

January 27, 2025

Patients With SLE Show Reduced mRNA Vaccine Response

"Low vaccine efficacy in patients with systemic lupus erythematosus correlates with unique B cell endotypes and compromised T cell immunity , researchers report."

Conexiant

April 29, 2024

A Look Ahead at Rheumatology in 2024

A rheumatologist reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024.

Conexiant